Sommetrics news

VISTA, Calif. — September 29, 2021 — Sommetrics, a private company developing products and services to improve sleep health, today announced the launch of the pivotal clinical trial of its aerSleep® II device for the treatment of obstructive sleep apnea (OSA). This study is being conducted at 10 university and community-based sleep centers in the U.S. under an Investigational Device Exemption approved by the Food and Drug Administration. Termed the SUPRA study (Study Using Neg

VISTA, Calif. — April 29, 2021 — Sommetrics is pleased to announce US Food and Drug Administration (FDA) approval of its Investigational Device Exemption (IDE) application to conduct a pivotal in-home clinical trial of its aerSleep II system.  The Study Using negative 

VISTA, Calif. — NOVEMBER 17, 2020 — Sommetrics, a private company developing products and services to improve sleep health, today announced its lead sleep apnea product, aerSleep II, has received FDA Breakthrough Device designation. This program allows for additional FDA feedback to sponsors during the pre-marketing phase but does not alter the basic requirements for market authorization. The Breakthrough Device program is intended to help patients gain more time

VISTA, Calif. — MAY 13, 2020 — Sommetrics, Inc. a company providing products and services to improve sleep quality, and its partially owned affiliate, aerFree, LLC, which is dedicated to improving acute airway management, t

VISTA, Calif. — JUNE 25, 2019 — Sommetrics a company dedicated to developing state of the art products to treat obstructive sleep apnea (OSA), today announced the completion of clinical study SOM-014. This trial evalua